TransUnion 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; fourth-quarter figures below are from the filing’s unaudited quarterly data. Amounts are in U.S. dollars.
Business context
TransUnion is a global information and analytics company providing credit reporting, risk analytics, identity verification, fraud prevention, marketing and consumer financial and identity-protection services. It reports U.S. Markets, International and Consumer Interactive segments. A substantial share of revenue comes from U.S. financial services and consumer credit activity.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $3,831.2 million (+3.3%) | $3,709.9 million |
| Operating income | $128.5 million | $626.3 million |
| Net income (loss) attributable to TransUnion | $(206.2) million | $266.3 million |
| Diluted earnings (loss) per share | $(1.07) | $1.38 |
| Adjusted EBITDA (non-GAAP) | $1,343.7 million; 35.1% margin | $1,344.9 million; 36.3% margin |
| Cash from operating activities | $645.4 million | $297.2 million |
| Capital expenditures | $310.7 million | $298.2 million |
| Total debt | $5,340.4 million | $5,670.1 million |
| Cash and cash equivalents | $476.2 million | $585.3 million |
FY 2023 operating income and GAAP earnings were sharply lower, principally reflecting a $414.0 million U.K. goodwill impairment, $75.3 million of restructuring expense and higher interest expense. Adjusted EBITDA was nearly flat year over year, while its margin declined 1.2 percentage points. The company reported a 3.6x leverage ratio, a non-GAAP measure. Its $600 million revolving facility had $598.8 million available at year-end, with no drawn balance; the company reported compliance with debt covenants.
Fourth quarter: Revenue was $954.3 million versus $902.1 million in Q4 2022. Operating income was $61.3 million versus $143.5 million, and net income attributable to TransUnion was $6.1 million versus $46.4 million.
Segments and changes versus prior period
- U.S. Markets: Revenue rose 2.3% to $2,504.2 million; Adjusted EBITDA fell 2.6% to $846.8 million, with margin down to 33.8% from 35.5%. Management cited higher variable product and people costs and a less favorable revenue mix. Financial Services growth was modest, with mortgage volumes pressured by higher rates and softness in FinTech and card/banking activity.
- International: Revenue increased 9.2% to $825.3 million (12.2% on a constant-currency basis); Adjusted EBITDA increased 9.8% to $361.5 million. India revenue grew 25.6%; U.K. revenue declined 2.8%, amid weak conditions and lower FinTech activity.
- Consumer Interactive: Revenue decreased 0.9% to $579.7 million and Adjusted EBITDA decreased 1.5% to $278.2 million. Lower direct-channel demand for paid credit products and reduced advertising were partly offset by indirect-channel breach revenue and volume.
Operating cash flow improved year over year, partly because 2022 included taxes paid on the Healthcare divestiture gain and higher incentive-compensation payments. Cash declined by $109.1 million during 2023. The company paid $81.8 million in dividends.
Outlook, risks and unusual items
- Transformation and investment: A plan approved in November 2023 targets operating-model optimization and technology modernization. The company expects $355–$375 million of total pre-tax costs through 2025, mostly by the end of 2024, and annual savings of $120–$140 million after completion. Capital expenditure is expected to rise to about 9% of revenue in 2024, then return to about 8% in 2025; management expects a longer-term reduction to about 6% of 2023 revenue. These are expectations, not guarantees.
- Macroeconomic exposure: Management cited elevated inflation, high interest rates, weaker lending and mortgage activity, and U.K. economic weakness. The U.K. reporting unit’s fair value was close to carrying value after impairment; specified adverse assumption changes could trigger additional impairment.
- Debt and rates: Debt is primarily variable-rate, with a reported year-end weighted-average interest rate of 7.33%; interest-rate swaps hedge portions of exposure. Interest expense rose to $288.2 million from $230.9 million. In February 2024, the company refinanced approximately $1.9 billion of Term Loan B-6 as Term Loan B-7 at SOFR plus 2.00%.
- Legal and regulatory matters: The CFPB’s ongoing consumer-marketing lawsuit carries a $56.0 million accrual; the company says an additional loss is reasonably possible but not estimable. Two other federal regulatory matters settled in 2023 for a combined $23.0 million, paid by year-end. A separate DOJ investigation concerning Argus data use under pre-acquisition government contracts remains unresolved; TransUnion accrued $37.0 million and recorded a related indemnification receivable.
- Financial reporting controls: Management and the auditor concluded internal control over financial reporting was ineffective at December 31, 2023, due to material weaknesses involving the interim U.K. goodwill impairment test and expense classification. Remediation is in progress. The financial-statement audit opinion was unqualified, but the auditor issued an adverse opinion on internal control effectiveness.
- Revisions: The company revised prior-period financial statements for expense-classification errors and an immaterial prior-year over-accrual; it also revised the supplemental 2022 cash-interest disclosure. The filing states the errors were not material to the statements taken as a whole. A goodwill-related control weakness also led to revision of 2023 interim statements.
Important facts for investors to verify
- Progress and realized costs and savings from the transformation plan, including technology spending and workforce changes.
- Whether U.K. performance stabilizes and whether further goodwill impairment is required.
- Resolution and potential financial exposure from the CFPB lawsuit and DOJ/Argus investigation, including the recoverability of the indemnification receivable.
- Remediation and independent testing of the material weaknesses, and any further financial-statement revisions.
- Debt refinancing terms, variable-rate exposure, cash generation and covenant capacity as the company funds investment and dividends.